Amicus Therapeutics : Termination of Material Agreement - Form 8-K
October 05, 2023 at 05:04 pm EDT
Share
Item 1.02. Termination of a Material Definitive Agreement.
As previously reported in its Current Report on Form 8-K filed on October 2, 2023, Amicus Therapeutics, Inc. (the "Company") entered into a Loan Agreement, dated October 2, 2023 (the "Loan Agreement"), by and among the Company, as the borrower, certain subsidiaries of the Company from time to time party thereto as guarantors, Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., as the "Blackstone Representative," and Wilmington Trust, National Association, as agent for certain lenders from time to time party thereto. In connection with the closing of the transactions contemplated by the Loan Agreement, the Company completed a voluntary prepayment of all outstanding obligations and paid the applicable prepayment premium, in the aggregate amount of $408,810,113, in each case pursuant to that certain Loan Agreement, dated July 17, 2020, by and among Amicus Therapeutics International Holding Ltd., the Company, certain subsidiaries of the Company, the lenders party thereto, and Hayfin Services LLP (the "Hayfin Loan Agreement"). The Hayfin Loan Agreement was accordingly terminated effective October 5, 2023.
A summary of the material terms of the Hayfin Loan Agreement is set forth in Item 1.01 of the Company's Current Report on Form 8-K filed on July 17, 2020 and are incorporated herein by reference.
Amicus Therapeutics Inc. published this content on 05 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 October 2023 21:03:10 UTC.
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
AMICUS THERAPEUTICS, INC. 
